Send to

Choose Destination
J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S82-8. doi: 10.1016/j.jaad.2015.07.053.

Treatment of hidradenitis suppurativa with biologic medications.

Author information

Dermatology Clinic, University of California San Diego, San Diego, California. Electronic address:
Department of Dermatology, University of California Davis, Sacramento, California.


Given the absence of significant improvement in the treatment of hidradenitis suppurativa (HS) with traditional medical and surgical therapies, biologics have piqued the interest of research investigators. The efficacy of biologics in the treatment of inflammatory conditions like psoriasis and rheumatoid arthritis is well-documented. More recently, success with biologics has been demonstrated in atopic dermatitis, another dermatological condition associated with inflammatory states. Researchers have begun to probe the utility of biologic agents in less prevalent conditions that feature inflammation as a key characteristic, namely, hidradenitis suppurativa. Five agents in particular adalimumab, anakinra, etanercept, infliximab, and ustekinumab, have been explored in the setting of HS. Results to date put forward adalimumab and infliximab as biologic treatments that can safely be initiated with some expectant efficacy. Other biologic agents require more rigorous examination before they are worthy of addition to the treatment armamentarium.


acne inversa; adalimumab; anakinra; biologics; etanercept; hidradenitis suppurativa; infliximab; treatment; tumor necrosis factor–alfa; ustekinumab

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center